4.4 Article

Cystic Fibrosis HRCT Scores Correlate Strongly With Pseudomonas Infection

期刊

PEDIATRIC PULMONOLOGY
卷 44, 期 11, 页码 1107-1117

出版社

WILEY
DOI: 10.1002/ppul.21107

关键词

cystic fibrosis; chest HRCT; Pseudomonas infection; pulmonary function

资金

  1. Cystic Fibrosis Foundation
  2. NCRR [M01-RR00037]
  3. Genentech, Inc [Z1970n]

向作者/读者索取更多资源

Background: In order to establish a valid surrogate outcome measure, it must be shown that the outcome measure (chest HRCT scores in cystic fibrosis [CF] patients) demonstrates strong statistical association with established endponts of disease, such as Pseudomonas aeruginosa (Pa) airway acquisition, acute exacerbations, or mortality. Methods: We estimated and tested the association between Pa infection status (Pa+ vs. Pa-) and baseline chest HRCT scores in 25 children with mild-to-moderate CF lung disease. For comparison, we estimated the association between Pa status and pulmonary function tests (PFTs), chest X-rays (CXR) scores, and BMI. Pa acquisition was determined from respiratory culture results and systematic review of clinic notes. Results: All subjects had respiratory cultures performed prior to or at baseline with a median of 19 months of retrospective culture observation (SD = 15.7 months, range: 0-52.5 months). The difference between age-adjusted mean total HRCT score for Pa+ versus Pa- was highly significant (P< 0.00001) with a near-perfect separation between scores in Pa+ versus Pa- patients. Similar results were found for several HRCT sub-scores. Among PFTs, only residual volume-to-total lung capacity (RV/TLC) had a significant difference between group means (P=0.03), but the overlap between groups in RV/TLC measurements was large. Conclusions: CF HRCT scores correlate highly with Pa acquisition, a clinically meaningful measure of progressing CF lung disease. HRCT scores are highly sensitive at predicting Pa acquisition status, while most PFT measures, chest radiograph (CXR) scores, and body mass index are not. These results provide further evidence that HRCT is appropriate for use in patient care and as an outcome measure in clinical trials. Pediatr Pulmonol. 2009; 44:1107-1117. (C) 2009 Wiley-Liss, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据